Optimal PSA Threshold for Obtaining MRI-Fusion Biopsy in Biopsy-Naïve Patients

Figure 1

Cumulative frequency of clinically significant prostate cancer with increasing PSA for targeted plus standard biopsy compared to standard biopsy alone. (a) Cumulative frequencies across all PSA ranges reported. (b) Cumulative frequencies across a small PSA range to illustrate the region where the two curves begin to diverge. csPCA = clinically significant prostate cancer; PSA = prostate-specific antigen.

(a)

(b)